These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 15337632)

  • 1. Follow-up measurements of Nevirapine plasma levels over a prolonged period.
    Sienz M; Zilly M; Ebigbo A; Knipper A; Winzer R; Klinker H; Langmann P
    Eur J Med Res; 2004 Aug; 9(8):412-6. PubMed ID: 15337632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
    Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.
    Almond LM; Edirisinghe D; Dalton M; Bonington A; Back DJ; Khoo SH
    Clin Pharmacol Ther; 2005 Aug; 78(2):132-42. PubMed ID: 16084848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir.
    Donnerer J; Haas BJ; Kessler HH
    Pharmacology; 2008; 82(4):287-92. PubMed ID: 18931536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of plasma antiretroviral drug monitoring in the management of HIV infected patients].
    Tréluyer JM
    Ann Med Interne (Paris); 2000 Jun; 151(4):291-6. PubMed ID: 10922957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
    J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
    J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily dosing of nevirapine in HAART.
    Clotet B
    J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.
    Rakhmanina NY; Capparelli EV; van den Anker JN; Williams K; Sever JL; Spiegel HM; Soldin SJ
    Ther Drug Monit; 2007 Feb; 29(1):110-7. PubMed ID: 17304158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.
    Duong M; Buisson M; Peytavin G; Kohli E; Piroth L; Martha B; Grappin M; Chavanet P; Portier H
    Ann Pharmacother; 2005 Apr; 39(4):603-9. PubMed ID: 15713788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
    Jackson JB; Parsons T; Musoke P; Nakabiito C; Donnell D; Fleming T; Mirochnick M; Mofenson L; Fowler MG; Mmiro F; Guay L
    AIDS; 2006 Jan; 20(2):217-22. PubMed ID: 16511414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
    Autar RS; Wit FW; Sankote J; Mahanontharit A; Anekthananon T; Mootsikapun P; Sujaikaew K; Cooper DA; Lange JM; Phanuphak P; Ruxrungtham K; Burger DM
    Antivir Ther; 2005; 10(8):937-43. PubMed ID: 16430199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
    Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
    Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
    Parienti JJ; Massari V; Reliquet V; Chaillot F; Le Moal G; Arvieux C; Vabret A; Verdon R;
    AIDS; 2007 Oct; 21(16):2217-22. PubMed ID: 18090049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Pérez H; Vignoles M; Laufer N; Gómez A; Coll P; Lottner J; Rolón M; Salomón H; Cahn P
    Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefit of interventions driven by therapeutic drug monitoring.
    Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
    HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Clin Pharmacol; 2005 Mar; 45(3):265-74. PubMed ID: 15703362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.